Press releases

29 October, 2014

Regulatory

Annual General Meeting 2015 and information about members appointed to the Nomination Committee

The Annual General Meeting in NeuroVive Pharmaceutical AB (publ) will be held on Wednesday 29 April, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.

11 September, 2014

Addendum: OnCore License

At the request of NASDAQ OMX Stockholm, the Company provides the following information regarding the license agreement referred to in the press release dated September 9, 2014.

9 September, 2014

Regulatory

NeuroVive signs USD 150 m agreement with OnCore BioPharma for the outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection

NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, has signed an exclusive global outlicensing agreement with the US biotechnology company OnCore BioPharma, Inc. related to the deve ...

20 August, 2014

Regulatory

NeuroVive: Interim Report 1 Jan. 2014 to 30 Jun. 2014

NeuroVive's research wins award at international research symposium

14 August, 2014

Regulatory

Enrollment to phase II study on NeuroSTAT® continues

Enrollment to the ongoing clinical phase IIa study with NeuroVive's drug candidate NeuroSTAT® for treating patients with severe traumatic brain injury (TBI) is continuing, and another two patients hav ...

10 June, 2014

Regulatory

NeuroVive’s research into energy regulation wins award at international research symposium

NeuroVive, a leading mitochondrial medicine company, participated in the international research symposium Mitochondrial Medicine 2014 held in Pittsburgh, USA, on 4-7 June. NeuroVive presented research ...

4 June, 2014

Regulatory

NeuroVive signs new agreement with Hospices Civils de Lyon

NeuroVive is extending its collaboration with Hospices Civils de Lyon (HCL) and Professor Ovize, which broadens the scope of NeuroVive's cardiovascular business area and creates the right conditions f ...

9 May, 2014

Regulatory

Report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) today, 9 May 2014. A summary of the resolutions follows. All decisions received the required majorities.

9 May, 2014

Regulatory

NeuroVive: Interim report 1 Jan. 2014 till 31 Mar. 2014

Successful rights issue and final patient treated in phase III study on CicloMulsion®

17 April, 2014

Regulatory

NeuroVive presents medical breakthrough in cellular energy regulation

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level. Based on the UK company Selcia Ltd's medical chemist ...

17 April, 2014

Regulatory

NeuroVive Pharmaceutical’s 2013 Annual Report now available

Today, NeuroVive Pharmaceutical AB (publ) announced that the Annual Report for 2013 is available as PDF at www.neurovive.com, and can be read via the link below. The available report is in Swedish. An ...

10 April, 2014

Regulatory

NeuroVive Stock Now Trading in the USA on the OTC Market

NeuroVive Pharmaceutical AB stock shares were registered with the OTC Reporting Facility for Foreign shares in New York City with the ticker symbol NEVPF:US on March 20, 2014. NeuroVive trades on the ...